Brief: Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia
14/05/2025 23:45
May 14 (Reuters) - Biohaven Ltd BHVN.N: FDA EXTENDS PDUFA DATE OF BIOHAVEN'S TRORILUZOLE NDA FOR RARE DISEASE SPINOCEREBELLAR ATAXIA BIOHAVEN LTD - FDA'S DECISION REGARDING NDA IS NOW EXPECTED IN 4Q 2025. Source text: ID:nPn6YwSwKa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing